{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:25:58Z","timestamp":1793827558147,"version":"4.6.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor\u2013associated immune thrombocytopenia (ICI-ITP) has been described in case reports and small case series, but comprehensive data on its incidence, risk factors, clinical features, treatment, and outcomes are lacking. We reviewed medical records of all adults initiating ICI therapy between 2016 and 2023 at 29 US hospitals across 7 major cancer centers to identify patients with ICI-ITP. Multivariable logistic regression was used to identify risk factors, and Cox modeling was performed to assess the association between ICI-ITP, its severity, and mortality. Among 86\u2009467 patients, ICI-ITP occurred in 214 (0.25%). Independent risk factors included lower baseline platelet count, combination ICI therapy, stage IV cancer, and additional immune-related adverse events. ICI-ITP occurred at a median of 8 weeks (interquartile range [IQR], 4-18) after ICI initiation, with a median nadir platelet count of 41 \u00d7 109\/L (IQR, 17 \u00d7 109\/L to 64 \u00d7 109\/L). Patients were treated with glucocorticoids (n = 106 [49.5%]), immune globulin (n = 39 [18.2%]), and thrombopoietin receptor agonists (n = 29 [13.6%]). Recovery occurred in 161 patients (75.2%) at a median of 2.3 weeks (IQR, 1.0-5.3). Of 76 patients rechallenged with ICIs, 23 (30.3%) developed recurrent ICI-ITP. ICI-ITP and its severity were associated with higher all-cause mortality, with a nearly threefold increase in risk among patients with severe ICI-ITP than those without ICI-ITP (adjusted hazard ratio, 2.96 [95% confidence interval, 2.14-4.08]). These findings establish ICI-ITP as a rare but clinically significant complication of ICI therapy, provide, to our knowledge, the first large-scale description of its risk factors and clinical course, and underscore the importance of timely recognition and management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031449","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T19:13:24Z","timestamp":1765221204000},"page":"1351-1364","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Immune thrombocytopenia in patients treated with immune checkpoint inhibitors"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-8779","authenticated-orcid":false,"given":"Rebecca K.","family":"Leaf","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Mass General Brigham Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1327-775X","authenticated-orcid":false,"given":"Jodi V.","family":"Mones","sequence":"additional","affiliation":[{"name":"3Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5660-6111","authenticated-orcid":false,"given":"Tushar","family":"Shenoy","sequence":"additional","affiliation":[{"name":"4Division of Renal Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Warsame","sequence":"additional","affiliation":[{"name":"5Department of Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7449-9789","authenticated-orcid":false,"given":"Marina","family":"Beltrami-Moreira","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2614-1605","authenticated-orcid":false,"given":"Sandhya","family":"Panch","sequence":"additional","affiliation":[{"name":"7Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"8Division of Hematology\/Oncology, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Leavitt","sequence":"additional","affiliation":[{"name":"9Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA"},{"name":"10Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Zon","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, MA"},{"name":"11Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen K.","family":"Kendall","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shahamatdar","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan L.","family":"Lim","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4736-4330","authenticated-orcid":false,"given":"Can","family":"Cui","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-3585","authenticated-orcid":false,"given":"Debbie","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Mass General Brigham Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-1408","authenticated-orcid":false,"given":"Sarah A.","family":"Kaunfer","sequence":"additional","affiliation":[{"name":"4Division of Renal Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6547-2564","authenticated-orcid":false,"given":"Lavanya","family":"Durai","sequence":"additional","affiliation":[{"name":"4Division of Renal Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Hoge","sequence":"additional","affiliation":[{"name":"4Division of Renal Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3039-9529","authenticated-orcid":false,"given":"Julie-Alexia","family":"Dias","sequence":"additional","affiliation":[{"name":"4Division of Renal Medicine, Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"13Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Sha","sequence":"additional","affiliation":[{"name":"3Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"14Department of Medicine, New York\u2013Presbyterian\/Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-773X","authenticated-orcid":false,"given":"Aaron N.","family":"Holmes","sequence":"additional","affiliation":[{"name":"3Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"14Department of Medicine, New York\u2013Presbyterian\/Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5282-1031","authenticated-orcid":false,"given":"Neela","family":"Easton","sequence":"additional","affiliation":[{"name":"3Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"14Department of Medicine, New York\u2013Presbyterian\/Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0077-9750","authenticated-orcid":false,"given":"Elizabeth M.","family":"Corley","sequence":"additional","affiliation":[{"name":"3Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"14Department of Medicine, New York\u2013Presbyterian\/Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Zhao","sequence":"additional","affiliation":[{"name":"3Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"14Department of Medicine, New York\u2013Presbyterian\/Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyi","family":"Li","sequence":"additional","affiliation":[{"name":"3Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"14Department of Medicine, New York\u2013Presbyterian\/Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Spelman","sequence":"additional","affiliation":[{"name":"15Section of Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Briggs","family":"Amos","sequence":"additional","affiliation":[{"name":"15Section of Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Soebbing","sequence":"additional","affiliation":[{"name":"15Section of Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Shabih","sequence":"additional","affiliation":[{"name":"15Section of Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Jamison","sequence":"additional","affiliation":[{"name":"15Section of Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8508-9371","authenticated-orcid":false,"given":"Bolun","family":"Liu","sequence":"additional","affiliation":[{"name":"5Department of Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guleid","family":"Hussein","sequence":"additional","affiliation":[{"name":"5Department of Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-1408","authenticated-orcid":false,"given":"Sumeet","family":"Yadav","sequence":"additional","affiliation":[{"name":"5Department of Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7963-2438","authenticated-orcid":false,"given":"Mohamed I.","family":"Elsaid","sequence":"additional","affiliation":[{"name":"16Division of Biostatistics and Population Health, Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH"},{"name":"17Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight H.","family":"Owen","sequence":"additional","affiliation":[{"name":"17Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Meara","sequence":"additional","affiliation":[{"name":"17Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick K.","family":"Juras","sequence":"additional","affiliation":[{"name":"18Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6874-9734","authenticated-orcid":false,"given":"Arvind","family":"Suresh","sequence":"additional","affiliation":[{"name":"10Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Heskel","sequence":"additional","affiliation":[{"name":"10Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-9389","authenticated-orcid":false,"given":"Jennifer J.","family":"Huang","sequence":"additional","affiliation":[{"name":"7Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"8Division of Hematology\/Oncology, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-9097","authenticated-orcid":false,"given":"Ilya G.","family":"Glezerman","sequence":"additional","affiliation":[{"name":"19Renal Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"20Department of Medicine, Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"21Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Mass General Brigham Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Mass General Brigham Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6817-5761","authenticated-orcid":false,"given":"Michael H.","family":"Kroll","sequence":"additional","affiliation":[{"name":"15Section of Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7875-090X","authenticated-orcid":false,"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, MA"},{"name":"4Division of Renal Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2026031911222090400_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"issue":"5","key":"2026031911222090400_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Tan","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"8","key":"2026031911222090400_bib3","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"6","key":"2026031911222090400_bib4","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"issue":"2","key":"2026031911222090400_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2026031911222090400_bib6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"36","key":"2026031911222090400_bib7","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026031911222090400_bib8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"2026031911222090400_bib9","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"8","key":"2026031911222090400_bib10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026031911222090400_bib11","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"2026031911222090400_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","article-title":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis","volume":"103","author":"Petrelli","year":"2018","journal-title":"Eur J Cancer"},{"issue":"25","key":"2026031911222090400_bib13","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"2026031911222090400_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"2026031911222090400_bib15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajh.25448","article-title":"Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors","volume":"94","author":"Leaf","year":"2019","journal-title":"Am J Hematol"},{"key":"2026031911222090400_bib16","doi-asserted-by":"crossref","first-page":"bcr2017221801","DOI":"10.1136\/bcr-2017-221801","article-title":"Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin","volume":"2018","author":"Algaze","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"3","key":"2026031911222090400_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000377650","article-title":"Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report","volume":"38","author":"Wo\u017aniak","year":"2015","journal-title":"Oncol Res Treat"},{"issue":"7","key":"2026031911222090400_bib18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/CAD.0000000000000520","article-title":"Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab","volume":"28","author":"Turgeman","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"2","key":"2026031911222090400_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.14740\/wjon1464","article-title":"Hemophagocytic lymphohistiocytosis secondary to immune checkpoint inhibitor therapy","volume":"13","author":"Rajapakse","year":"2022","journal-title":"World J Oncol"},{"key":"2026031911222090400_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2026031911222090400_bib21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2026031911222090400_bib22","doi-asserted-by":"crossref","first-page":"23699","DOI":"10.1038\/s41598-024-75271-x","article-title":"Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors","volume":"14","author":"Mo","year":"2024","journal-title":"Sci Rep"},{"key":"2026031911222090400_bib23","doi-asserted-by":"crossref","first-page":"111606","DOI":"10.1016\/j.intimp.2024.111606","article-title":"PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: a pharmacovigilance study and systematic review","volume":"129","author":"Moore","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"2026031911222090400_bib24","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"2026031911222090400_bib25","unstructured":"National Cancer Institute\n          . Common Terminology Criteria for Adverse Events (CTCAE) v6.0. Accessed 30 August 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events#ctcae."},{"issue":"2","key":"2026031911222090400_bib26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"11","key":"2026031911222090400_bib27","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026031911222090400_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/bloodadvances.2019000868","article-title":"A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia","volume":"4","author":"Al-Samkari","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2026031911222090400_bib29","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ajh.23562","article-title":"Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists","volume":"88","author":"Makar","year":"2013","journal-title":"Am J Hematol"},{"key":"2026031911222090400_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026031911222090400_bib31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"2026031911222090400_bib32","doi-asserted-by":"crossref","first-page":"2487767","DOI":"10.1080\/09537104.2025.2487767","article-title":"Immune-induced thrombocytopenia by pembrolizumab: case report and review of literature","volume":"36","author":"El-Ghazzi","year":"2025","journal-title":"Platelets"},{"issue":"20","key":"2026031911222090400_bib33","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.3390\/cancers14205030","article-title":"Immune checkpoint inhibitor-related cytopenias: about 68 cases from the French pharmacovigilance database","volume":"14","author":"Martin","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"25","key":"2026031911222090400_bib34","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/bloodadvances.2017010942","article-title":"Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry","volume":"1","author":"Arnold","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"2026031911222090400_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2026031911222090400_bib36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2015.1.237","article-title":"Bleeding complications in immune thrombocytopenia","volume":"2015","author":"Arnold","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"23","key":"2026031911222090400_bib37","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"2026031911222090400_bib38","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2012.04664.x","article-title":"Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia","volume":"10","author":"Arnold","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026031911222090400_bib39","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/jth.14419","article-title":"The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a diagnostic test","volume":"17","author":"Vrbensky","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026031911222090400_bib40","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1182\/blood.V87.10.4068.bloodjournal87104068","article-title":"Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction","volume":"87","author":"Emmons","year":"1996","journal-title":"Blood"},{"issue":"6","key":"2026031911222090400_bib41","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.hoc.2009.09.001","article-title":"Thrombopoietin and platelet production in chronic immune thrombocytopenia","volume":"23","author":"Kuter","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"2026031911222090400_bib42","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"2026031911222090400_bib43","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ejim.2016.09.001","article-title":"Response of first line treatment with corticosteroids in a population-based cohort of adults with primary immune thrombocytopenia","volume":"37","author":"Frederiksen","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"9610","key":"2026031911222090400_bib44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"2026031911222090400_bib45","doi-asserted-by":"crossref","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2026031911222090400_bib46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"issue":"25","key":"2026031911222090400_bib47","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026031911222090400_bib48","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026031911222090400_bib49","doi-asserted-by":"crossref","first-page":"e009061","DOI":"10.1136\/jitc-2024-009061","article-title":"Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab","volume":"12","author":"Maloney","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"15","key":"2026031911222090400_bib50","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood.2024024230","article-title":"Mitigation of checkpoint inhibitor-induced autoimmune hemolytic anemia through modulation of purinergic signaling","volume":"144","author":"Dei Zotti","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2026031911222090400_bib51","first-page":"912","article-title":"Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"33","author":"Cruz Carreras","year":"2025","journal-title":"Support Care Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/12\/1351\/2509343\/blood_bld-2025-031449-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/12\/1351\/2509343\/blood_bld-2025-031449-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:22:34Z","timestamp":1773933754000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/12\/1351\/557132\/Immune-thrombocytopenia-in-patients-treated-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,3,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031449","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,19]]},"published":{"date-parts":[[2026,3,19]]}}}